Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026

Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026
 
 Summary

 The Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026 gives a COVID-19 disease overview, epidemiology overview, current marketed vaccines, unmet needs, pipeline assessment, and market outlook.
 
 The analyst forecast three different potential scenarios for the future use of COVID-19 vaccines -
 - The first scenario assumes that annual vaccination with a COVID-19 vaccine will be needed.
 - The second scenario assumes annual vaccination for the high-risk population of people 65 years of age and older, while everyone below 65 years of age will need a vaccine only every two years.
 - In the third scenario, the high-risk population of people 65 years of age and older will receive a COVID-19 vaccine every two years, while everyone below 65 years will need a vaccine only every five years.
 
 Scope
 This report includes -
 - Executive Summary
 - Disease Overview: History of the outbreak, Etiology and Pathophysiology
 - Epidemiology
 - Current Vaccination Options: Includes detailed product profiles with SWOT analysis
 - Unmet Need and Opportunities: Detailing the major unmet needs with significant KOL insights
 - Pipeline Assessment: Includes pipeline overview and detailed product profiles with SWOT analysis
 - R&D Strategies: Trends in Clinical Trial Design for COVID-19 Vaccines and Trends in Deal-Making
 - Market Outlook
 
 Reasons to Buy
 - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
 - Develop business strategies by understanding the trends shaping and driving the 7MM COVID-19 vaccine.
 - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global COVID-19 vaccine market in the future.
 - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
 - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
 - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

1 Executive Summary
2 Disease Overview
3 Epidemiology
4 Current Vaccination Options
5 Unmet Needs and Opportunities
6 Pipeline Assessment
7 R&D Strategies
8 Market Outlook
9 Appendix
10 Contact Us

Companies Mentioned
- Pfizer
- BioNTech
- Moderna
- AstraZeneca
- Johnson & Johnson
- Novavax
- CureVac
- Sanofi
- GlaxoSmithKline
- Arcturus
- Medicago
- Valneva
- Inovio


Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the

USD 2495 View Report

Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021

Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021 provides an overview of Coronavirus

USD 2500 View Report

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the

USD 2495 View Report

Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021

Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021 provides an overview of Coronavirus

USD 2500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available